ASH 2023 – Ramón García-Sanz

Ramón García-Sanz gives insights into the assessment of residual disease in multiple myeloma and explains future clinical implications of these data. Moreover, he discusses in which ways the evaluation of minimal residual disease might improve the management of patients with Waldenström macroglobulinemia and shares his personal highlight from the ASH 2023 congress.

Here is the full ASH 2023 report.

More posts